Representatives from Advanced Diagnostics/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab.
Now open for recruitment, OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'.Ģ2/05/12 Advanced Diagnostics Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine 24/10/12 Advanced Diagnostics Begins Centralised Testing for Major Clinical Trial.HSL Advanced Diagnostics is now offering PD-L1 IHC testing using the Dako pharmDx 22C3 companion diagnostic for Pembrolizumab.Ģ8/01/13 Advanced Diagnostics Validates New ALK IHC Assay for NSCLCĪdvanced Diagnostics validates the new Roche Tissue Diagnostics ALK IHC assay for use in Non Small Cell Lung Cancer (NSCLC) patients for whom Crizotinib (Xalkori, Pfizer) is being considered.
The HSL-AD service is also able to take in additional referral work to help maintain services under pressure. There is currently no disruption to normal services.